Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Processa Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.

Get PCSA alerts

About James Neal

James Neal is recorded as Board Member at Processa Pharmaceuticals, Inc. (PCSA) since January 1, 2022. The newest filing on record that lists James Neal as Board Member at Processa Pharmaceuticals, Inc. (PCSA) is dated June 18, 2026. Earlier roles on record: Board Member at XOMA Royalty Corp until January 1, 2023 and CEO at XOMA Royalty Corp until December 31, 2022. The proxy statement of XOMA Royalty Corp reports total compensation of $3,510,795 for James Neal in fiscal 2021, including a base salary of $593,166. Disclosed compensation is on record for 4 fiscal years. Processa Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Processa Pharmaceuticals, Inc. includes George Ng (CEO and Board Member), Russell L. Skibsted (CFO), Russell Skibsted (CFO) and 7 others.

Affiliation history

  • Processa Pharmaceuticals, Inc. (PCSA)

    Board Member

    Proxy statement

    Current

    2022-01-01–present

    Last confirmed June 18, 2026

  • XOMA Royalty Corp

    Board Member

    Proxy statement

    Start not stated–2023-01-01

  • XOMA Royalty Corp

    CEO

    Proxy statement

    Start not stated–2022-12-31

Company network

XOMA Royalty Corp

Biotechnology · Healthcare

Board Member, CEO

Leadership on record at Processa Pharmaceuticals, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2021 XOMA Royalty Corp $593,166 $3,510,795
2020 XOMA Royalty Corp $533,527 $1,693,762
2019 XOMA Royalty Corp $498,623 $1,479,559
2018 XOMA Royalty Corp $484,100 $1,323,455

Recent activity

No call appearances or filed executive changes recorded yet.